These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Development of second generation EP2 antagonists with high selectivity. Ganesh T; Jiang J; Dingledine R Eur J Med Chem; 2014 Jul; 82():521-35. PubMed ID: 24937185 [TBL] [Abstract][Full Text] [Related]
5. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Jiang J; Dingledine R Trends Pharmacol Sci; 2013 Jul; 34(7):413-23. PubMed ID: 23796953 [TBL] [Abstract][Full Text] [Related]
7. Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells. Kay LJ; Gilbert M; Pullen N; Skerratt S; Farrington J; Seward EP; Peachell PT Clin Exp Allergy; 2013 Jul; 43(7):741-51. PubMed ID: 23786281 [TBL] [Abstract][Full Text] [Related]
8. Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models. Amaradhi R; Banik A; Mohammed S; Patro V; Rojas A; Wang W; Motati DR; Dingledine R; Ganesh T J Med Chem; 2020 Feb; 63(3):1032-1050. PubMed ID: 31904232 [TBL] [Abstract][Full Text] [Related]
9. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Jiang J; Ganesh T; Du Y; Quan Y; Serrano G; Qui M; Speigel I; Rojas A; Lelutiu N; Dingledine R Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3149-54. PubMed ID: 22323596 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Jiang J; Yang MS; Quan Y; Gueorguieva P; Ganesh T; Dingledine R Neurobiol Dis; 2015 Apr; 76():126-136. PubMed ID: 25600211 [TBL] [Abstract][Full Text] [Related]
12. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. Jiang J; Dingledine R J Pharmacol Exp Ther; 2013 Feb; 344(2):360-7. PubMed ID: 23192657 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of prostaglandin E(2) on the migration of nasal fibroblasts. Shin JM; Park IH; Moon YM; Hong SM; Cho JS; Um JY; Lee HM Am J Rhinol Allergy; 2014; 28(3):e120-4. PubMed ID: 24980222 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: involvement of protein kinase C-θ activation. Takahashi T; Uehara H; Ogawa H; Umemoto H; Bando Y; Izumi K Oncotarget; 2015 Mar; 6(7):4829-44. PubMed ID: 25638159 [TBL] [Abstract][Full Text] [Related]
15. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Meja KK; Barnes PJ; Giembycz MA Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541 [TBL] [Abstract][Full Text] [Related]
16. Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus. Nagib MM; Yu Y; Jiang J Pharmacol Ther; 2020 May; 209():107504. PubMed ID: 32088247 [TBL] [Abstract][Full Text] [Related]
17. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Liang X; Wang Q; Shi J; Lokteva L; Breyer RM; Montine TJ; Andreasson K Ann Neurol; 2008 Sep; 64(3):304-14. PubMed ID: 18825663 [TBL] [Abstract][Full Text] [Related]